Sarclisa + SOC approved in the US for adult patients with newly diagnosed multiple myeloma not eligible for transplant September 24, 2024
FDA approves BORUZU, a new presentation of bortezomib for ready-to-use subcutaneous administration or IV administration September 10, 2024
Alecensa Approved in Japan for the Additional Indication of Adjuvant Treatment for People with ALK-Positive Early-Stage NSCLC September 3, 2024
European Commission Approves BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) for the treatment of adult patients with advanced NSCLC with a BRAFV600E mutation September 3, 2024
European Commission approves RYBREVANT (amivantamab) + chemo for adult patients with advanced EGFR-mutated NSCLC after failure of prior therapy September 3, 2024
European Commission Approves PADCEV (enfortumab vedotin) + KEYTRUDA (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer September 3, 2024
RYBREVANT (amivantamab-vmjw) + LAZCLUZE (lazertinib) approved in the U.S. for patients with EGFR-mutated advanced lung cancer August 27, 2024
EU Approves TEPKINLY® (epcoritamab) for the Treatment of Adults with R/R Follicular Lymphoma August 27, 2024
European Commission approves BALVERSA (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma August 27, 2024
Lynparza and Imfinzi combination approved in the EU for patients with MMR-proficient advanced or recurrent endometrial cancer August 22, 2024
FDA approves Imfinzi + chemo for treatment of adult patients with resectable early-stage (IIA-IIIB) EGFR/ALK WT NSCLC August 22, 2024
MHRA approves Zolbetuximab for the treatment of Claudin18.2+ve, HER2neg gastric/GEJ cancer August 21, 2024
Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer August 21, 2024
FDA Approves LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with R/R Cutaneous T-Cell Lymphoma August 13, 2024
DARZALEX FASPRO® (daratumumab & hyaluronidase-fihj)-based quadruplet regimen approved in the US for patients with newly diagnosed transplant-eligible multiple myeloma August 7, 2024
FDA grants Accelerated Approval to TECELRA® (afamitresgene autoleucel) for advanced MAGE-A4+synovial sarcoma in chemo-treated adults August 7, 2024
FDA expands Jemperli (dostarlimab) + chemo approval to all adult patients with primary advanced or recurrent endometrial cancer with demonstrated OS benefit August 6, 2024
RYBREVANT (amivantamab) + chemo approved in the EU for 1L treatment of patients with advanced NSCLC with activating EGFR ex 20 insertion mutations July 9, 2024
Tagrisso + chemo approved in the EU as new 1L treatment for patients with EGFR-mutated advanced lung cancer July 9, 2024
Tagrisso + chemo approved in China & Japan as 1st-line treatment for patients with EGFR-mutated advanced lung cancer July 1, 2024
US FDA Grants Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with R/R Follicular Lymphoma July 1, 2024
